Background/Aim: A lymphokine, the vascular permeability factor (VPF), which increases vascular permeability, has been characterized in minimal-change nephrotic syndrome (MCNS). Transforming growth factor-β (TGF-β) is an immunosuppressive cytokine that inhibits proliferation, cytokine production, and cytotoxic activity of T cells and natural killer cells. We, therefore, investigated the effects of TGF-β1 on the release of VPF by peripheral blood T cells from MCNS patients. The aim of our study was to determine the in vitro immunosuppressive capacity of TGF-β1 in patients with MCNS. Methods: To further test the effect of TGF-β1 on concanavalin A (Con A)-induced VPF release, normal and MCNS T cells were stimulated with 5 µg/ml of Con A in the presence or absence of TGF-β1, and the culture supernatants were tested for the presence of VPF by the method of Lagrue et al. The disease controls included 16 patients with IgA nephropathy. Results: Significantly increased spontaneous and Con A-stimulated secretion of VPF was detected in T-cell cultures of MCNS patients with the nephrotic syndrome as compared with those of normal controls. Addition of TGF-β1 to these cultures inhibited the release of VPF in a dose-dependent manner. The effect of TGF-β1 on the release of VPF was specific, since a reversion was obtained with a neutralizing monoclonal antibody to human TGF-β1. Conclusion: Together, our data demonstrate that TGF-β1 antagonizes the ability of T cells to release VPF, and suggest a role of TGF-β1 in the pathophysiology of VPF in vitro.

Keywords:
Minimal-change nephrotic syndrome, IgA nephropathy, Nephrotic syndrome, Vascular permeability factor, Transforming growth factor-β
1.
Lagrue G, Xheneumont S, Branellec A, Hirbec G, Weil B: Vascular permeability factor elaborated from lymphocytes. I. Demonstration in patients with nephrotic syndrome. Biomedicine 1975;23:37–40.
2.
Heslan JMJ, Branellec AI, Pilatte Y, Lang P, Lagrue G: Differentiation between vascular permeability factor and IL-2 in lymphocyte supernatants from patients with minimal-change nephrotic syndrome. Clin Exp Immunol 1991;86:157–162.
3.
Boulton-Jones JM, Tulloch I, Dore B, McLay A: Changes in the glomerular capillary wall induced by lymphocyte products and serum of nephrotic patients. Clin Nephrol 1983;20:72–77.
4.
Yoshizawa N, Kusumi Y, Matsumoto K, Oshima S, Takeuchi A, Kawamura O, Kubota T, Kondo S, Niwa H: Studies of a glomerular permeability factor in patients with minimal-change nephrotic syndrome. Nephron 1989;51:370–376.
5.
Matsumoto K: Interleukin-10 inhibits vascular permeability factor release by peripheral blood mononuclear cells in patients with lipoid nephrosis. Nephron 1997;75:154–159.
6.
Matsumoto K, Ohi H, Kanmatsuse K: Interleukin-10 and interleukin-13 synergize to inhibit vascular permeability factor release by peripheral blood mononuclear cells from patients with lipoid nephrosis. Nephron 1997;77:212–218.
7.
Matsumoto K, Ohi H, Kanmatsuse K: Interleukin-4 cooperates with interleukin-10 to inhibit vascular permeability factor release by peripheral blood mononuclear cells from patients with minimal-change nephrotic syndrome. Am J Nephrol 1999;19:21–27.
8.
Wahl S, McCartney-Francis N, Mergenhagen S: Inflammatory and immunomoduratory roles of TGF-β. Immunol Today 1989;10:258–261.
9.
Ahuja S, Paliogianni F, Yamada H, Balow J, Boumpas D: Effect of transforming growth factor-β on early and late activation events in human T cells. J Immunol 1993;150:3109–3118.
10.
Tsunawaki S, Sporn M, Ding A, Nathan C: Deactivation of macrophages by transforming growth factor-β. Nature 1988;334:260–262.
11.
Powire F, Carlino FJ, Leach MW, Mauze S, Coffman RL: A critical role for transforming growth factor-β but not interleukin-4 in the suppression of T helper type-1 mediated colitis by CD45RB low CD4+ T cells. J Exp Med 1996;183:2669–2674.
12.
Schena FP: A retrospective analysis of the natural history of primary IgA nephropathy worldwide. Am J Med 1990;89:209–215.
13.
Tijssen P: Practice and Theory of Enzyme Immunoassays. Amsterdam, Elsevier, 1985.
14.
Wardle EN: Minimal-change nephrosis and allergy. Nephron 1996;74:422–423.
15.
Garin EH, Boggs KP: Synergy of monocytes and lymphocytes from idiopathic minimal lesion nephrotic patients in relapse in the production of the supernatant factor that increases rat glomerular basement membrane sulfate uptake. Int J Pediatr Nephrol 1987;8:187–192.
16.
Yap HK, Cheung W, Murugasu B, Sim SK, Seah CC, Jordan C: Th1 and Th2 cytokine mRNA profiles in childhood nephrotic syndrome: Evidence for increased IL-13 mRNA expression in relapse. J Am Soc Nephrol 1999;10:529–537.
17.
Takeda T, Nakagawa Y, Narita I, Kimura H, Kutsuwada T, Arakawa M: Identification and characterization of specifically expressed genes in mononuclear cells from patients with glomerulosclerosis (abstract). J Am Soc Nephrol 1995;6:854.
18.
Chantry D, Turner M, Abney E, Feldmann M: Modulation of cytokine production by TGF-β. J Immunol 1989;142:4295–4300.
19.
Baricos WH, Cortez SL, Deboisblanc M, Xin S: Transforming growth factor-β is a potent inhibitor of extracellular matrix degradation by cultured human mesangial cells. J Am Soc Nephrol 1999;10:790–795.
20.
Schmitt E, Hoehn P, Huels C, Goedert S, Palm N, Rüde E, Germann T: T-helper type 1 development of naive CD4+ T cells requires the coordinate action of interleukin-12 and interferon-γ and is inhibited by transforming growth factor-β. Eur J Immunol 1994;24:739–798.
21.
Hunter CA, Bermudez L, Beernink H, Waegell W, Remington JS: Transforming growth factor-β inhibits interleukin-12-induced production of interferon-γ by natural killer cells: A role for transforming growth factor-β in the regulation of T cell-independent resistance to Toxoplasma gondii. Eur J Immunol 1995;25:994–1000.
22.
Wahl S: Transforming growth factor-β: The good, the bad, and the ugly. J Exp Med 1994;180:1587–1590.
23.
Daniel V, Trautmann Y, Konrad M, Nayir A, Schärer K: T-lymphocyte populations, cytokines and other growth factors in serum and urine of children with idiopathic nephrotic syndrome. Clin Nephrol 1997;47:289–297.
24.
Culpepper JA, Lee F: Regulation of interleukin-3 expression by glucocorticoids in cloned murine T lymphocytes. J Immunol 1985;135:3191–3197.
© 2001 S. Karger AG, Basel
2001
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.